Evidence map›Paper›PMID 42137584›Full record

ArticleMolecular therapy. Advances2026

In-utero cell transplantation for hypophosphatasia with gene-edited hESC-derived MSCs in a murine model.

Naoya Kitamura, Akihiro Hasegawa, Aki Takahashi-Nakamura, Masataka Kasahara, Hidenori Akutsu, Haruhiko Sago, Osamu Samura, Aikou Okamoto, Akihiro Umezawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naoya KitamuraCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Akihiro HasegawaCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Aki Takahashi-NakamuraDepartment of Pharmacology, Tokyo Dental College, Tokyo 101-0061, Japan.
Masataka KasaharaDepartment of Pharmacology, Tokyo Dental College, Tokyo 101-0061, Japan.
Hidenori AkutsuCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Haruhiko SagoInternational University of Health and Welfare, Chiba 286-8520, Japan.
Osamu SamuraDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Aikou OkamotoDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Akihiro UmezawaCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo 157-8535, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The perinatal severe form of hypophosphatasia (HPP), caused by a deficiency in tissue-nonspecific alkaline phosphatase (TNAP), which is involved in bone metabolism, is a disease that manifests during fetal development. However, no established treatment can be performed in utero, and invasive treatment must be continued for a lifetime immediately after birth due to irreversible thoracic hypoplasia. We have developed an

Indexed as

ex vivo in-utero gene cell therapyfetal therapyHPPhuman embryonic stem cellhypophosphatasiaimmunotoleranceintraperitoneal cell injectionmesenchymal stem cellsmesenchymal stromal cellstissue-nonspecific alkaline phosphataseTNAP

Identifiers

PMID42137584
PMCPMC13148942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.